https://prabadinews.com/
  • October 7, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

Bemarituzumab Elicits Positive Overall Survival in FGFR2b-Positive First-Line Gastric Cancer

Bemarituzumab Elicits Positive Overall Survival in FGFR2b-Positive First-Line Gastric Cancer

The fibroblast growth factor receptor 2b (FGFR2b)-inhibiting bemarituzumab demonstrated improvements in overall survival and other key secondary end points compared with placebo in first-line gastric cancer.

administrator

Related Articles